Metabolism, distribution and elimination of lisdexamfetamine dimesylate: Open-label, single-centre, phase I study in healthy adult volunteers

Clinical Drug Investigation

Volumn 28, Issue 12, 2008, Pages 745-755

  Krishnan, Suma M ^a,b,e   Pennick, Michael ^c   Stark, Jeffrey G ^d  

^a Belvedere CA   (United States)

^b New River Pharmaceuticals   (United States)

^c Shire Pharmaceuticals   (United Kingdom)

^d CEDRA Corporation   (United States)

^e NONE   (United States)

Author keywords

Central nervous system stimulants, pharmacokinetics; Lisdexamfetamine, pharmacokinetics

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; HIPPURIC ACID; LISDEXAMFETAMINE;

ADULT; AGITATION; ALLERGIC RHINITIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COUGHING; DEPRESSION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ELECTROCARDIOGRAM; EUPHORIA; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; XEROSTOMIA;

ADULT; DEXTROAMPHETAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; TISSUE DISTRIBUTION;

EID: 55849092101     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/0044011-200828120-00002     Document Type: Article

References (34)

1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366 (9481): 237-48
2. Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003; 2 (2): 104-13
3. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007; 190: 402-9
4. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163 (4): 716-23
5. Goldman LS, Genel M, Bezman RJ, et al. for the Council on Scientific Affairs, American Medical Association. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998; 279 (14): 1100-7
6. Cantwell DP. Attention deficit disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1996; 35 (8): 978-87
7. Pliszka SR, Crismon ML, Hughes CW, et al. and the Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/Hyperactivity Disorder. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45 (6): 642-57
8. American Academy of Pediatrics Subcommittee on Attention-Deficit/ Hyperactivity Disorder Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics 2001; 108 (4): 1033-44
9. Greenhill LL, Pliszka S, Dulcan MK, et al. and the Work Group on Quality Issues. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41 (2 Suppl.): 26S-49S
10. Wilens TE, Dodson W. A clinical perspective of attention-deficit/ hyperactivity disorder into adulthood. J Clin Psychiatry 2004; 65 (10): 1301-13
11. Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995; 52 (6): 434-43
12. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001; 58 (8): 775-82
13. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006; 11 (8): 625-39
14. Wood DR, Reimherr FW, Wender PH, et al. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry 1976; 33 (12): 1453-60
15. Connor DF, Steingard RJ. New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential. CNS Drugs 2004; 18 (14): 1011-30
16. Wilens TE, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006; 45 (4): 408-14
17. White BP, Becker-Blease KA, Grace-Bishop K. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. J Am Coll Health 2006; 54 (5): 261-8
18. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003; 160 (11): 1909-18
19. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995; 52 (6): 456-63
20. Farré M, Camí J. Pharmacokinetic considerations in abuse liability evaluation. Br J Addict 1991; 86 (12): 1601-6
21. Schuster CR. History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. Drug Alcohol Depend 2006; 83 Suppl. 1: S8-S14
22. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/ hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007; 29 (3): 450-63
23. Shojaei A, Ermer JC, Krishnan S. Lisdexamfetamine dimesylate as a treatment for ADHD: dosage formulation and pH effects [poster NR 740]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego (CA)
24. Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. Epub 2008 Jul 17
25. Ermer JC, Shojaei AH, Biederman J, et al. Improved interpatient pharmacokinetic variability of lisdexamfetamine dimesylate compared with mixed amphetamine salts extended release in children aged 6 to 12 years with attention-deficit/hyperactivity disorder [poster NR 750]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego (CA)
26. Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007; 62 (9): 970-6
27. Biederman J, Krishnan S, Hodgkins P, et al. Efficacy and safety of lisdexamfetamine (NRP104) in children aged 6 to 12 years with attention-deficit/hyperactivity disorder (ADHD) [poster NR 632]. 159th Annual Meeting American Psychiatric Association; 2006 May 20-25; Toronto (ON)
28. Asatoor AM, Galman BR, Johnson JR, et al. The excretion of dexamphetamine and its derivatives. Br J Pharmacol Chemother 1965; 24: 293-300
29. Vyvanse [package insert]. Wayne (PA): Shire US Inc., 2008
30. Krishnan SM, Stark JG. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin 2007; 24 (1): 33-40
31. Adderall XR (mixed salts of a single entity amphetamine product) [package insert]. Wayne (PA): Shire US Inc., 2007
32. Wong YN, Wang L, Hartman L, et al. Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers. J Clin Pharmacol 1998; 38 (10): 971-8
33. Krishnan S, Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. J Clin Pharmacol 2008; 48 (3): 293-302
34. Cody JT, Valtier S, Nelson SL. Amphetamine enantiomer excocaine? cretion profile following administration of Adderall. J Anal Toxicol 2003; 27 (7): 485-92